Skip to content

H.R. 3093 · 118th Congress (2023–2025)

Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2023

This bill requires companies that receive federal funding for research (or a license of the rights to a patent or regulatory test data) for a biomedical product or service to agree to set reasonable prices for the resulting biomedical product or service.

The Department of Health and Human Services (HHS) must determine a reasonable price based on a formula that ensures the U.S. price for the product or service is not more than the median price for the product or service in Canada and six other reference countries with, based on specified criteria, large economies and high incomes.

Companies entering these agreements also must report to HHS certain financial information related to the biomedical product or service involved.

Show official title

To require persons who undertake federally funded research and development of a biomedical product or service to enter into reasonable pricing agreements with the Secretary of Health and Human Services, and for other purposes.

Expired in House committee

Derived from the legislative history, not an official disposition.

Latest actionReferred to Health

This bill’s path

This is H.R. 3093’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed House

  3. Passed Senate

  4. Sent to President

  5. Signed into law

  6. Expired

Sponsor
Rep. Val T. Hoyle (D-OR-4)
Cosponsors
18 cosponsors

14 original · 4 later

18 D

  1. Rep. Steve Cohen (D-TN-9)· Original · May 5, 2023
  2. Rep. Rosa L. DeLauro (D-CT-3)· Original · May 5, 2023
  3. Rep. Lloyd Doggett (D-TX-37)· Original · May 5, 2023
  4. Rep. Raúl M. Grijalva (D-AZ-7)· Original · May 5, 2023
  5. Rep. Jesús G. "Chuy" García (D-IL-4)· Original · May 5, 2023
  6. Rep. Pramila Jayapal (D-WA-7)· Original · May 5, 2023
  7. Rep. Marcy Kaptur (D-OH-9)· Original · May 5, 2023
  8. Rep. Ro Khanna (D-CA-17)· Original · May 5, 2023
  9. Del. Eleanor Holmes Norton (D-DC)· Original · May 5, 2023
  10. Rep. Chellie Pingree (D-ME-1)· Original · May 5, 2023
  11. Rep. Mark Pocan (D-WI-2)· Original · May 5, 2023
  12. Rep. Janice D. Schakowsky (D-IL-9)· Original · May 5, 2023
  13. Rep. Melanie A. Stansbury (D-NM-1)· Original · May 5, 2023
  14. Rep. Jill N. Tokuda (D-HI-2)· Original · May 5, 2023
  15. Rep. Greg Casar (D-TX-35)· Later · May 26, 2023
  16. Rep. Mark Takano (D-CA-39)· Later · Jun 7, 2023
  17. Rep. Seth Magaziner (D-RI-2)· Later · Jun 13, 2023
  18. Rep. Rashida Tlaib (D-MI-12)· Later · Aug 4, 2023
Policy area
Health
Subjects
  • Government information and archives
  • Health care costs and insurance
  • Prescription drugs

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in House

    Document: Introduced in House

    Sources
  2. Latest
    ▸ 2 committee actions · May 5, 2023 – May 12, 2023
    1. Referred to committee

      Referred to the House Committee on Energy and Commerce.

      Sources
    2. Referred to Health

      Referred to the Subcommittee on Health.

      Sources
  3. Expired

    Introduced → Referred to House Health → No further action before the 118th Congress ended.

Committees

  1. HouseEnergy and CommerceReferred May 5, 2023
  2. HouseHealthReferred May 12, 2023

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in House
Titles (2)
  1. Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2023

    Display title, Short title · Introduced in House

  2. To require persons who undertake federally funded research and development of a biomedical product or service to enter into reasonable pricing agreements with the Secretary of Health and Human Services, and for other purposes.

    Official title · Introduced in House